NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · FORA · USD
Stock price, earnings
Quote as of May 15, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Forian Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Forian Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Forian Inc. delivers advanced software solutions, proprietary data insights, and sophisticated predictive analytics. These offerings are designed to enhance the operational efficiency, clinical effectiveness, and financial stability of its diverse clientele, which spans the healthcare, cannabis, and government sectors. The company structures its operations into three primary segments: Information & Software, Services, and Other. Among its key product lines, Forian provides several critical tools for the cannabis industry. BioTrack is a comprehensive, vertically integrated software system that supports dispensaries, cultivators, manufacturers, and distributors with point-of-sale, production, and delivery management. Complementing this is Cannalytics, a Software as a Service (SaaS) analytics platform that offers clients a clear overview of their business performance. Furthermore, Forian offers robust compliance solutions like the BioTrack seed-to-sale platform, which facilitates the tracking and tracing of cannabis products from cultivation through to final sale. Its BioTrack State Traceability & Enforcement Monitoring System (STEMS) is specifically tailored for regulatory agencies, providing a module for cannabis program management and ensuring transparency and accountability across the supply chain. Beyond its core software and data offerings, Forian also extends its services to include security monitoring and web marketing. The company is based in Newtown, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Nov 13, 2024 | $0.03+200.0% vs estimate | $4.69M-2.37% vs estimate |
|---|
| Q2 2024 | Aug 14, 2024 | -$0.08-366.67% vs estimate | $4.78M-9.87% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$33.80+$0.07 (+0.21%)
HealthStream, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.08% below the high.
$23.49+$0.02 (+0.09%)
NRC Health’s quoted price sits in the upper half of its reported 52-week range, 3.73% below the high.
$13.01+$0.08 (+0.62%)
NeuroPace, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.62% below the high.
$3.04+$0.28 (+10.14%)
Eledon Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.91% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.78% below the high.
$4.05-$0.15 (-3.57%)
ImageneBio Inc’s quoted price sits in the lower half of its reported 52-week range, 54.75% below the high.
$10.35$0.00 (0.0%)
Finch Therapeutics Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.71% below the high.
